logo

Clinical Trial Results

Share

Japan's Takeda Pharmaceutical Co. Ltd. (TKPYY.PK) announced Thursday that new phase 3 data show investigational subcutaneous or SC formulation of Vedolizumab meets primary endpoint in achieving clinical remission at week 52 in patients with moderately to severely active ulcerative colitis. The VISIBLE...

Genentech, a member of the Roche Group (RHHBY), said that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival or PFS and demonstrated that the combination of Tecentriq, or atezolizumab, plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of...

pharma-gainers-071818.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-july17.jpg The following are some of today's top gainers in the pharma/biotech sector.

Genentech, a member of the Roche Group (RHHBY), announced Tuesday that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications from the flu met the study's primary objective. The study showed superior efficacy in the primary endpoint...

pharma-gainers-071817.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-daily-071118.jpg Shares of Zogenix Inc. (ZGNX) are up over 20% in pre-market trading on Thursday, following positive top-line results from its second confirmatory phase III study of its investigational drug, ZX008 for the treatment of children and young adults with Dravet syndrome.

pharma-gainers-071118.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-gainers-071018.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-gainers-070918.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-daily-070518.jpg Today's Daily Dose brings you news about favorable results from Eisai/Biogen's phase II study of BAN2401 in Alzheimer's; MabVax' delisting from the Nasdaq; Regulus' workforce reduction; FDA approval of fully wristed, 60mm stapler and Zynerba pulling the plug on THC Prodrug ZYN001.

Swedish research-based biopharma company BioArctic AB (publ) announced late Thursday positive topline results from the Phase 2b study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease. The study achieved statistical significance on key efficacy...

pharma-gainers-070518.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-gainers-070418.jpg The following are some of today's top gainers in the pharma/biotech sector.

daily-gainers-070218.jpg The following are some of today's top gainers in the pharma/biotech sector.

Follow RTT